Amgen’s Surprise Aflibercept Launch Shakes Up US Biosimilars In 2024
As Market Approaches Tenth Anniversary Of First Biosimilars Approval And Launch
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.
